Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility-Reference-Cited by-同舟云学术

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility

Published:2010-05-20 Issue:1 Volume:225 Page:256-265
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Ghedini Gaia C.,Ciravolo Valentina,Tortoreto Monica,Giuffrè Sarah,Bianchi Francesca,Campiglio Manuela,Mortarino Mimosa,Figini Mariangela,Coliva Angela,Carcangiu Maria L.,Zambetti Milvia,Piazza Tiziana,Ferrini Silvano,Ménard Sylvie,Tagliabue Elda,Pupa Serenella M.

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference45 articles.

1. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation;Aigner;Oncogene,2001

2. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer;Ali;Cancer,2008

3. Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials;Ali;J Clin Oncol,2009

4. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation;Anido;EMBO J,2006

5. Protein ectodomain shedding;Arribas;Chem Rev,2002

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope;Proceedings of the National Academy of Sciences;2024-01-16

2. Resistance to Trastuzumab;Cancers;2022-10-19

3. Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples;ACS Sensors;2020-09-10

4. Multiomic analysis of cytokines in immuno-oncology;Expert Review of Proteomics;2020-09-01

5. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment;Cellular Oncology;2019-08-02